MCRB - セレス・セラピュ―ティックス (Seres Therapeutics Inc.) セレス・セラピュ―ティックス

 MCRBのチャート


 MCRBの企業情報

symbol MCRB
会社名 Seres Therapeutics Inc (セレス・セラピュ―ティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 セレス・セラピューティクス(Seres Therapeutics Inc.)はマイクロバイオーム治療プラットフォーム会社である。同社はエコビオティック微生物治療薬という生物薬の開発に従事する。同社の医薬品は、ジビオティック微生物の機能を修復することによって健康を回復するように設計される。同社は、結腸微生物の不全症を治療するエコビオティック・マイクロビオム治療法を開発するために、その微生物治療プラットフォームを実施する。SER-109はクロストリジウム・ディフィシル感染症(CDI)のさらなる再発を防ぐために設計されたリード製品候補である。同社は、主要なCDIの初期再発を防ぐためのSER-262、潰瘍性大腸炎を含む炎症性腸疾患(IBD)を治療するためのSER-287およびSER-301、並びに腸内細菌病原体を治療するためのSER-155を含む他の製品候補を開発する。   セレス・セラピュ―ティックスは米国のマイクロバイオ―ム治療法プラットフォ―ム開発企業。生物学的薬剤を開発し、腸内の微生物群であるマイクロバイオ―ムの機能を元に戻す治療法に取り組む。クロストリジウム・ディフィシル感染症の再発を防ぐSER-109、潰瘍性大腸炎を治療するSER-287、抗生物質抵抗性バクテリアを処理するSER-155を開発する。   Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.
本社所在地 200 Sidney Street - 4th Floor Cambridge MA 02139 USA
代表者氏名 Roger Pomerantz ロジャー・ポメラント
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 617-945-9626
設立年月日 40452
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 138人
url www.serestherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/mcrb
adr_tso
EBITDA EBITDA(百万ドル) -85.82700
終値(lastsale) 6.77
時価総額(marketcap) 276186638.51
時価総額 時価総額(百万ドル) 266.39570
売上高 売上高(百万ドル) 34.65400
企業価値(EV) 企業価値(EV)(百万ドル) 170.32970
当期純利益 当期純利益(百万ドル) -91.59400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Seres Therapeutics Inc revenues increased 42% to $8.6M. Net loss increased 4% to $55.7M. Revenues reflect Collaboration revenue - related party increase of 33% to $8M. Higher net loss reflects Research and development expenses increase of 10% to $43.3M (expense) Interest income decrease of 75% to $349K (income) General and administrative expenses increase of 6% to $13.1M (expense).

 MCRBのテクニカル分析


 MCRBのニュース

   Seres Therapeutics stock slips on $100M stock offering  2022/06/30 11:36:07 Seeking Alpha
Seres Therapeutics (MCRB) shares dropped ~8% pre-market after the microbiome therapeutics company launched a $100M offerinf of common stock.Then offering consists of 31,746,030 shares…
   NVAX, SAFM and MCRB among after hour mover  2022/06/21 21:23:41 Seeking Alpha
Gainers: Novavax (NVAX) +259%. Precision BioSciences (DTIL) +114%
   MCRB,CKPT and RDBX among pre market gainers.  2022/06/16 12:17:44 Seeking Alpha
Redbox Entertainment (RDBXW) +70%. Sidus Space (SIDU) +45%.Redbox Entertainment (RDBX) +18%. Seres Therapeutics (MCRB) +13%. Checkpoint Therapeutics (CKPT) +12%
   Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens  2022/06/09 16:08:19 Seeking Alpha
Seres Therapeutics reports new data concerning safety and effectiveness of SER-109 for treating recurrent C.difficile infection. Read more on MCRB stock here.
   79 Biggest Movers From Yesterday  2022/06/08 08:08:00 Benzinga
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC ) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company''s pūrgo technology, classifying it as a class II medical device. Applied UV, Inc. (NASDAQ: AUVI ) gained 96.4% to close at $2.18. Kiromic BioPharma, Inc. (NASDAQ: KRBP ) shares jumped 74.3% to close at $0.5020 on Tuesday after the company entered a sponsored research agreement under which in vivo preclinical data will be generated from Kiromic''s Gamma Delta T cell allogeneic therapies. JanOne Inc. (NASDAQ: JAN ) shares gained 62.8% to settle at $4.07 after the company announced that a patent was issued that covers a method of improving nerve function using JAN101. Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) rose 61.8% to close at $1.15. Accelerate Diagnostics, last month, posted a Q1 loss of $0.25 per share. Oncorus, Inc. (NASDAQ: ONCR ) rose 48.7% to close at $1.65. Energy Focus, Inc. (NASDAQ: EFOI ) gained 46.2% to settle at $2.28.
   Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2022 Results - Earnings Call Transcript  2022/05/04 17:12:18 Seeking Alpha
Seres Therapeutics, Inc. (NASDAQ:NASDAQ:MCRB) Q1 2022 Earnings Conference Call May 04, 2022 08:30 AM ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President…
   Seres Therapeutics GAAP EPS of -$0.61 misses by $0.09, revenue of $1.49M  2022/05/04 11:11:11 Seeking Alpha
Seres Therapeutics press release (MCRB): Q1 GAAP EPS of -$0.61 misses by $0.09.Revenue of $1.49M (-74.0% Y/Y).
   Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates  2022/05/04 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported first quarter 2022 financial results and provided business updates. “Seres continued to make important progress toward bringing SER-109 to patients suffering with recurrent C. difficile infection (rCDI). Given the robust profile of SER-109 observed in our Phase 3 study, we expect the product to have a significant impact on rCDI, a serious disease with approximate
   Seres Therapeutics Q1 2022 Earnings Preview (NASDAQ:MCRB)  2022/05/03 15:03:29 Seeking Alpha
Seres Therapeutics (MCRB) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open.The consensus EPS Estimate is -$0.50 (-28.2% Y/Y) and the consensus…
   Analysts Say That Seres Therapeutics Inc. (NASDAQ:MCRB) Is Likely To Make It To $32.00 In 12 Months  2022/04/30 12:30:00 Marketing Sentinel
In last trading session, Seres Therapeutics Inc. (NASDAQ:MCRB) saw 0.62 million shares changing hands with its beta currently measuring 3.40. Company’s recent per share price level of $4.73 trading at -$0.14 or -2.87% at ring of the bell on the day assigns it a market valuation of $465.95M. That closing price of MCRB’s stock is … Analysts Say That Seres Therapeutics Inc. (NASDAQ:MCRB) Is Likely To Make It To $32.00 In 12 Months Read More »
   Seres Therapeutics Q1 2022 Earnings Preview (NASDAQ:MCRB)  2022/05/03 15:03:29 Seeking Alpha
Seres Therapeutics (MCRB) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open.The consensus EPS Estimate is -$0.50 (-28.2% Y/Y) and the consensus…
   Analysts Say That Seres Therapeutics Inc. (NASDAQ:MCRB) Is Likely To Make It To $32.00 In 12 Months  2022/04/30 12:30:00 Marketing Sentinel
In last trading session, Seres Therapeutics Inc. (NASDAQ:MCRB) saw 0.62 million shares changing hands with its beta currently measuring 3.40. Company’s recent per share price level of $4.73 trading at -$0.14 or -2.87% at ring of the bell on the day assigns it a market valuation of $465.95M. That closing price of MCRB’s stock is … Analysts Say That Seres Therapeutics Inc. (NASDAQ:MCRB) Is Likely To Make It To $32.00 In 12 Months Read More »
   Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022  2022/04/28 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (NASDAQ: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2022 at 8:30 a.m. ET to discuss first quarter 2022 results and provide a general business update. To access the conference call, please dial 877-270-2148 (domestic) or 412-902-6510 (international) and request to be joined to the Seres Therapeutics call. To join the live webcast, please v
   MCRB, BLU and WOOF among after hour movers  2022/04/20 21:49:57 Seeking Alpha
Gainers: Universal Display Corporation (OLED) +10%. United Airlines Holdings (UAL) +8%
   Destiny Pharma undervalued compared to peers, suggests finnCap  2022/04/12 11:42:00 Proactive Investors UK
Destiny Pharma’s 29021 year-end cash of £4.65mln together with a £6.5mln fundraise in March 2022 provides a funding runway into mid-2023, says house broker finnCap. “With several companies active in the NTCD-M3 data room, we look forward to the company securing a partner to co-fund the Phase 3 trial. “Final regulatory discussions (with FDA and EMA) for the Phase 3 trial design are due to be finalised in H1 2022, which should catalyse partnering discussions.“ The broker’s target price remains 306p, which it adds implies an enterprise value of £220mln and also recognises the upside potential given the substantially higher valuations for companies focused on CDI (NYSE:CDI) recurrence such as Seres Therapeutics (NASDAQ:MCRB) “that arguably have less compelling profiles than NTCD-M3”.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セレス・セラピュ―ティックス MCRB Seres Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)